
The CRISPR Patent War: ToolGen’s Strategic Leverage in the US, Europe, and the UPC
As ToolGen secures key CRISPR-Cas9 RNP patents in the US and Europe, the landscape for gene-editing licensing shifts, signaling a high-stakes showdown at the Unified Patent Court.































